The Danish pharmaceutical group Novo Nordisk plans to deepen its collaborations with various companies within the multi-billion dollar market for weight loss medications in the United States. According to Karsten Munk Knudsen, the company’s CFO, who spoke to Handelsblatt, Novo Nordisk is establishing direct agreements with American employers. These types of arrangements are already being developed for individual companies that intend to offer partial reimbursement for obesity medications. Such contracts would allow employers to subsidize or partially cover the cost of anti-obesity drugs for their employees, treating them as a form of workplace benefit.
Economy / Finance
